限局期小細胞肺癌（LS-SCLC）に対する通常の化学放射線療法（CRT）治療への新規免疫療法薬アテゾリズマブ（MPDL3280A）の追加試験

基本情報

NCT ID

NCT03811002

ステータス

実施中（募集終了）

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

544

治験依頼者名

National Cancer Institute (NCI)

概要

This phase III trial studies how well chemotherapy and radiation therapy (chemoradiation) with or without atezolizumab works in treating patients with limited stage small cell lung cancer. Drugs used in chemotherapy, such as etoposide, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving chemoradiation with or without atezolizumab may work better in treating patients with limited stage small cell lung cancer.

対象疾患

介入

依頼者（Sponsor）

実施施設 (10)